GNI Group: Extraordinary Report
GNI Group: Notice of presentation of research paper on F351
GNI Group: Notice Concerning Issuance of Stock Acquisition Rights (Paid Stock Options)
GNI Group: Gyre Therapeutics Announces Additions to Russell 2000 and Russell 3000 Indices
GNI Group: Notice regarding approval of F230 New Drug Clinical Trial Commencement Application (IND) in China
GNI Group: Notice of concurrent duties as an advisor to the executive officer and an officer
GNI Group: Your recent questions and answers
GNI Group: Quarterly Report - 1st quarter of the 24th period (2024/01/01 to 2024/03/31)
GNI Group: Confirmation letter
GNI Group: Fact book for the 1st quarter of the fiscal year ending 2024/12
GNI Group: Notice regarding the establishment of a joint venture with Oltz Co., Ltd. and Governance Partners Co., Ltd.
GNI Group: Notice regarding the conclusion of a business alliance (strategic partnership agreement) with Governance Partners Co., Ltd.
GNI Group: Notice regarding preparations for applying for a change in market classification to the Tokyo Stock Exchange Prime Market
GNI Group: Presentation of financial results for the 1st quarter of the fiscal year ending 2024/12
GNI Group: Consolidated financial results (IFRS) for the 1st quarter of fiscal year 2024
GNI Group: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
GNI Group: Gyre Therapeutics' 2024 1st Quarter Form 10-Q Disclosure
GNI Group: Ishare Analyst Report Update Notice
GNI Group: Gyre Therapeutics' press release on the 2024 1st quarter overview and business highlights
GNI Group: Notice of conclusion of a license agreement by our consolidated subsidiary Beijing Continent
No Data